Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 5/20 | 0.54 |
| ▸ | FABP1 | P07148 | 1/20 | 0.53 |
| ▸ | FABP6 | P51161 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | GALR3 | O60755 | 2/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31631318 | 1.00 | BACE1 (0.65) | BACE1EGFRFABP1FABP6APP | |
| SCHEMBL5212805 | 0.85 | APP (0.54) | BACE1APPKMT2AMEN1LMNA | |
| SCHEMBL7835214 | 0.85 | KDM4E (0.55) | BACE1EGFRAPPSMN1; SMN2PDE5A | |
| SCHEMBL11016635 | 0.85 | APP (0.54) | BACE1APPRAB9AKMT2AMEN1 | |
| SCHEMBL5646095 | 0.81 | APP (0.56) | BACE1EGFRAPPCDK1 | |
| SCHEMBL21382408 | 0.81 | NPC1 (0.62) | EGFRAPPNR2F2RAB9AKMT2A | |
| SCHEMBL10509411 | 0.81 | MAOA (0.58) | EGFRRAB9AKMT2AMEN1NPC1 | |
| SCHEMBL11263883 | 0.79 | ALDH1A1 (0.45) | BACE1RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL23269080 | 0.79 | EGFR (0.54) | BACE1EGFRFABP1FABP6GALR3 | |
| SCHEMBL11069733 | 0.79 | BACE1 (1.00) | BACE1EGFRFABP1FABP6APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077107-B2 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2021-08-03 | — | — | US | disclosed |
| US-20200283435-A1 | Autotaxin Inhibitory Compunds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| US-10654846-B2 | Autotaxin inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20190240219-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INT (DE) | 2019-08-08 | — | — | US | disclosed |
| US-10328074-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20180016274-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| US-20180016274-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
| EP-2925761-B1 | TRIAZOLOPYRAZINES AS BRD4 INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016124939-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-11 | — | — | WO | disclosed |
| US-20160129001-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20150051208-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051208-A1 | PYRIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| US-20140142098-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| US-20140142098-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
| WO-2014076237-A1 | TRIAZOLOPYRAZINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | WO | disclosed |
| CN-101723885-B | Improved method for preparing diaminopyridine | JUBILANT ORGANOSYS LTD | 2013-02-13 | — | — | CN | disclosed |
| CN-101723885-A | Improved method for preparing diaminopyridine | JUBILANT ORGANOSYS LTD | 2010-06-09 | — | — | CN | disclosed |
| JP-2005170848-A | METHOD FOR PRODUCING 2,3-DIAMINOPYRIDINES | KOEI CHEM CO LTD | 2005-06-30 | — | — | JP | disclosed |
| US-5023256-A | Antihistamines | DOMPE FARMACEUTICI S.P.A. (IT) | 1991-06-11 | — | — | US | disclosed |
| EP-0397613-A2 | Pharmacologically active aminoimidazopyridines | DOMPE' FARMACEUTICI S.p.A. (IT) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240219-A1 | TRIAZOLOPYRAZINE | MKI67, CCNI, CCNT2 | BACE1 3731/4885EGFR 1169/4885FABP1 4589/4885 |
| US-10654846-B2 | Autotaxin inhibitory compounds | ENPP2, RNASE1, ATXN10 | BACE1 1705/4885EGFR 2805/4885FABP1 2528/4885 |
| US-20200283435-A1 | Autotaxin Inhibitory Compunds | ENPP2, RNASE1, ATXN10 | BACE1 1816/4885EGFR 2779/4885FABP1 3199/4885 |
| US-20160129001-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS | BRD4, BRD3, BICRA | BACE1 2869/4885EGFR 2263/4885FABP1 3065/4885 |
| US-20140142098-A1 | TRIAZOLOPYRAZINE | MKI67, CCNI, CCNT2 | BACE1 3731/4885EGFR 1169/4885FABP1 4589/4885 |
| US-10328074-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors | BRD4, BRD3, BICRA | BACE1 2869/4885EGFR 2263/4885FABP1 3065/4885 |
| US-20150051208-A1 | PYRIDINONES | MKI67, XDH, CDK6 | BACE1 2651/4885EGFR 1381/4885FABP1 4303/4885 |
| US-11077107-B2 | Triazolopyrazine | MKI67, CCNI, CCNT2 | BACE1 3731/4885EGFR 1169/4885FABP1 4589/4885 |
| US-20180016274-A1 | AUTOTAXIN INHIBITORY COMPOUNDS | ENPP2, RNASE1, ATXN10 | BACE1 1705/4885EGFR 2805/4885FABP1 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.